Abstract Piflufolastat F 18 (PYLARIFY®) is an 18 F-labelled diagnostic imaging agent that
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …

Each year, new drugs are introduced to the market, representing structures that have affinity
for biological targets implicated in human diseases and conditions. These new chemical …

Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the
type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can …

Purpose In primary prostate cancer (PCa) patients, accurate staging and histologic grading
are crucial to guide treatment decisions. 18 F-DCFPyL (PSMA)-PET/CT has been …

Objective To assess whether a diagnostic pathway in which prostate‐specific membrane
antigen (PSMA) positron‐emission tomography (PET)/computed tomography (CT) is used as …

Fluorinated compounds are widely used in the fields of molecular imaging, pharmaceuticals,
and materials. Fluorinated natural products in nature are rare, and the introduction of …

Purpose Positron emission tomography imaging of zirconium-89-labelled monoclonal
antibodies (89Zr-Immuno-PET) allows for visualisation and quantification of antibody uptake …

OBJECTIVE. The purpose of this study was to assess the utility of PET with (2 S)-2-[[(1 S)-1-
carboxy-5-[(6-(18F) fluoranylpyridine-3-carbonyl) amino] pentyl] carbamoylamino] …

Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET
scans may be used to monitor treatment response in patients with prostate cancer (PCa). To …

Simple Summary Prostate-specific membrane antigen (PSMA)-targeted PET/CT imaging is
increasingly being used for (re) staging in prostate cancer. Although PSMA suggests …